PEDIATRIC ONCOLOGY - PowerPoint PPT Presentation

1 / 57
About This Presentation
Title:

PEDIATRIC ONCOLOGY

Description:

... (29%) mediastinal (7%) retroperitoneal (4%) cervical (3% ... Seventy-five per cent of tumours occur in the abdomen (adrenal medulla 50 %, paraspinal ... – PowerPoint PPT presentation

Number of Views:965
Avg rating:3.0/5.0
Slides: 58
Provided by: 5403126
Category:

less

Transcript and Presenter's Notes

Title: PEDIATRIC ONCOLOGY


1
PEDIATRIC ONCOLOGY
2
Leading causes of death of children between of 1
and 14
HIV infection 1 Homicide, 1
Suicide, 1
Pneumonia, 2
cerebral palsy 1
3
Distribution of cancer in children younger than
15 years of age by diagnosis
Acute lynphoblastic leucemia 23.3
CNS tumors 20.7
Neuroblastoma 7.3
Non-Hodgkin's 6.3
Wilms' tumor 6.1
Hodgkin's disease 5
Acute myeloid leukemia 4.2
Rhabdomypsarcoma 3.4
Retinoblastoma 2.9
Osteosarcoma 2.6
Other 2.1
4
Etiology and mechanisms of carcinogenesis.
  • Endogenous factors constitutional chromosomal
    abnormality mendelian autosomal dominant,
    recessive, or X-linked patterns non-mendelian
    inheritance mutations in multiple genes or
    mitochondrial DNA or caused by mutations
    affecting imprinted genes.

5
Etiology and mechanisms of carcinogenesis.
  • Exogenous factors
  • - physical agents most commonly studied are
    ultraviolet radiation, ionizing radiation, and
    extremely low-frequency (50-60 Hz) magnetic
    fields.
  • - chemical factors are environmental pollutants,
    tobacco, aflatoxin, and androgenic steroids.
  • - biologic agents.

6
Prenatal diagnosis of tumors (sonographic
features)
  • Absence or disruption of contour, shape,
    location, sonographic texture or size, of a
    normal anatomic structure
  • Presence of an abnormal structure or abnormal
    biometry
  • Abnormality in fetal movement
  • Polyhydramnios
  • Hydrops fetalis.

7
Common chief complaints given by parents that
suggest a pediatric cancer
Chief complaints Suggested cancer
Chronic drainage from ear Rhabdomyosarcoma Langerrhans cell histiocytosis
Morning headache with vomiting Brain tumor
Lump in neck that that does not respond to antibiotics Hodgkins or non- Hodgkins lymphomas
Swollen face and neck Non-Hodgkins lymphoma, leukemia
Mass in abdomen Wilms tumor, neuroblastoma, hepatoma
Bleeding from vagina Yolk sack tumor, rhabdomyosarcoma
Weight loss Hodgkins lymphoma
Bone pain Leukemia, neuroblastoma
8
Noninvasive imaging techniques
  • Plain film chest radiography
  • Plain films of the abdomen
  • Barium studies
  • Diagnostic ultrasound (US) examination
  • Computed tomography (CT)
  • Magnetic resonance imaging (MRI)
  • Tumor markers
  • Excisional and incisional biopsies

9
TERATOMAS
  • Teratomas are tumors comprising more than a
    single cell type derived from more than one germ
    layer. A significant degree of confusion has
    arisen regarding nomenclature for the various
    subtypes of teratomas. The word itself is derived
    from the Greek word teraton, meaning monster, and
    was used initially by Virchow in the first
    edition of his book on tumors, which was
    published in 1863. Teratomas range from benign,
    well-differentiated (mature) cystic lesions to
    those that are solid and malignant (immature).
    Besides being mature, with malignant
    transformation, teratomas also may be monodermal
    and highly specialized.

10
The most common location
  • sacrococcygeal (57)
  • gonads (29)
  • mediastinal (7)
  • retroperitoneal (4)
  • cervical (3)
  • intracranial (3)

11
Classification of the sacrococcygeal teratomas
  • Type I tumors are predominantly external,
    attached to the coccyx, and may have a small
    presacral component (45.8). No metastases were
    associated with this group.
  • Type II tumors have both an external mass and
    significant presacral pelvic extension (34) and
    have a 6 metastases rate.
  • Type III tumors are visible externally, but the
    predominant mass is pelvic and intraabdominal
    (8.6). A 20 rate of metastases was found in
    this group.
  • Type IV lesions are not visible externally but
    are entirely presacral (9.6) and have an 8
    metastases rate.

12
Malignant sacrococcygeal teratoma
Sacrococcygeal teratoma
                                  ltgt
                                  ltgt
Complications
13
Complications of the sacrococcygeal teratomas
  • associated congenital anomalies
  • pre-term labor and delivery
  • massive hemorrhage into the tumor with secondary
    fetal exsanguination
  • dystocia, secondary to tumor bulk or tumor
    rupture
  • placentomegaly and/or hydrops evolved, which, in
    turn, precipitated rapid fetal death

14
Differential diagnosis
  • ?eningomyelocele
  • rectal abscess
  • dermoid cyst
  • angioma
  • lipoma
  • neurogenic tumor
  • pilonidal cyst.

15
Treatment
  • Surgical, including removal of the coccyx.
  • Malignant surgical excision chemotherapy
    radiation (metastases to lung, bone, liver).

16
Prognosis of the sacrococcygeal teratomas
  • Benign - disease free survival is greater than
    90 malignant - significant mortality, although
    good progress has been made recently in treatment
    of these tumors.
  • Time of diagnoses is key
  • lt 2 months of age, only 7-10 are malignant
  • Age 1 year, 37 malignant
  • Age 2 years, 50 malignant

17
RHABDOMYOSARCOMA
  • A malignant tumor of mesenchimal cell origin is
    called a sarcoma. Mesenchymal cells normaly
    mature into skeletal muscle, smooth muscle, fat,
    fibrous tissue, bone, and cartilage.
    Rhabdomyosarcoma is thought to arise from
    immature mesenchimal cells that are committed to
    skeletal muscle lineage, but these tumors can
    arise in tissues in which striated muscle is not
    normally found, such as urinary bladder.
  • Rhabdomyosarcoma (RMS), the most common soft
    tissue sarcoma in infants and children,
    represents about 5-15 of all malignant solid
    lesions. RMS arises from a primitive cell type
    and occurs in mesenchymal tissue at almost any
    body site excluding brain and bone.

18
The Intergroup Rhabdomyosarcoma Study divides
tumors into 5 types
  • embryonal (57 ),
  • alveolar (19 ),
  • botryoid (6 ),
  • undifferentiated (17 ),
  • pleomorphic (1 ).

19
embryonic rhabdomyosarcoma of the vesica urinaria
                                                
                           ltgt
                                    ltgt
20
Orbital embryonic rhabdomyo-sarcoma
                                  ltgt
21
Alveolar rhabdomyosarcoma
                                  ltgt
                                                
                          ltgt
22
Diagnosis.
  • Biopsy (open, percutaneous, or endoscopic) is
    required for diagnosis and histological typing,
    which directs therapy. The extent of the tumour
    is defined by imaging techniques such as
    ultrasound, computed tomography (CT), or magnetic
    resonance imaging (MRI).

23
Treatment
  • is determined on an individual basis, according
    to the site, stage, and histological type of the
    tumor. Treatment of rhabdomyosarcoma should be
    multimodal, consisting of chemotherapy, surgery,
    and radiotherapy.

24
  • Surgery is the most rapid way to ablate the
    disease, and it should always be used if
    subsequent function or cosmetic will not be
    greatly impaired. In sites such as vagina and
    urinary bladder and most head and neck sites,
    incisional biopsy (for diagnosis) may be the only
    feasible surgical procedure because of proximity
    to vital blood vessels and nerves, cosmetic
    consideration, or both. The second-look operation
    is used to resect residual tumor after the
    administration chemotherapy or local radiotherapy.

25
  • Radiation therapy can eradicate residual tumor
    cells from sites where surgical therapy alone
    cannot ablate the mass, especially in the head,
    neck, and pelvis.

26
  • Preoperative chemotherapy may reduce the extent
    of surgery required and should be considered.
    Postoperative chemotherapy is helpful in
    eradicating residual disease and micrometastases.
    Chemotherapy is the primary treatment for
    patients with metastatic disease at presentation.
    The commonly used drugs are a combination of
    cyclophosphamide, vincristine, actinomycin D, and
    Adriamycin. Doxorubicin, DTIC (ditriazoimidazole
    carboximide), cisplatin, and ifosfamide have also
    been known to be effective agents.

27
Wilms tumor (nephroblastoma)
                                                
                          ltgt
28
  • Wilms tumor is thought to be caused by
    alterations of genes responsible for normal
    genitourinary development. Examples of common
    congenital anomalies associated with Wilms tumor
    are cryptorchidism, double collecting system,
    horseshoe kidney, and hypospadias. Environmental
    exposures, although considered, seem less likely
    to play a role.

29
Clinical
  • History. The most common presentation is an
    asymptomatic abdominal mass discovered by the
    parent or physician. Occasionally the child
    presents with haematuria, but symptoms are often
    non-specific abdominal fullness, abdominal pain,
    gastrointestinal upset, fever, weight loss,
    malaise, and anaemia. Hypertension is sometimes
    detectable.
  • A small number of patients who have hemorrhaged
    into their tumor may present with signs of
    hypotension, anemia, and fever. Rarely, patients
    with advanced-stage disease may present with
    respiratory symptoms related to the presence of
    lung metastases.

30
Cytogenetics studies
  • An 11p13 deletion as in the WAGR syndrome
    (Wilms, aniridia, genitourinary abnormalities,
    mental retardation)
  • A duplication of the paternal allele 11p15 as in
    BWS
  • Mutational analysis of the WT1 gene in cases
    where Denys-Drash syndrome (intersexual
    disorders, nephropathy, Wilms tumor) is suspected

31
Imaging Studies
  • Renal ultrasonography (with dynamic imaging of
    the renal vein and interior vena cava).
  • CT scanning. Abdominal CT scanning helps
    determine the tumor's origin, lymph node
    involvement, bilateral kidney involvement, and
    invasion into major vessels (eg, inferior vena
    cava or liver metastases). If findings on chest
    CT scanning are positive while chest radiographic
    findings are negative, diagnostic biopsy of the
    lesions noted on the chest CT scan is
    recommended.
  • Chest radiography (4-field) - Detects lung
    metastases (Patients with lung lesions on chest
    radiography receive whole lung radiotherapy.)

32
Wilms tumor (nephroblas-toma)
                                  ltgt
33
                                      ltgt
nephroblastoma angiograma
34
Leftside nephroblastoma (CT-scan)
                                                
                              ltgt
35
Current approach to Wilms tumor by stage and
histology
Stage, Histology Surgery Chemotherapy Radiotherapy
Stage I or II with FHStage I with anaplasia Nephrectomy VincristineDactinomycin None
Stage III or IV with FHStage II, III, or IV with focal anaplasia Nephrectomy VincristineDactinomycinDoxorubicin Yes
Stage II, III, or IV with diffuse anaplasiaStage I, II, III, or IV CCSK Nephrectomy VincristineDoxorubicinCyclophosphamideEtoposide Yes
Stage I, II, III, or IV RTK Nephrectomy CyclophosphamideEtoposideCarboplatin Yes
36
Complications.
  • The primary treatment, nephrectomy, may damage
    kidney function. However, additional treatment
    modalities may cause damage to several organs
    such as the heart, lungs, liver, bones, and
    gonads. In addition, both chemotherapeutic agents
    and radiation therapy can induce second malignant
    neoplasms.

37
NEUROBLASTOMA
  • Neuroblastoma is a tumour of neural crest origin
    which may occur in the adrenal medulla or
    anywhere along the sympathetic ganglion chain,
    namely in the neck, thorax, abdomen, and pelvis.
    Seventy-five per cent of tumours occur in the
    abdomen (adrenal medulla 50 , paraspinal ganglia
    25 ), 20 occur in the thorax, and 5 occur in
    the neck and the pelvis.

38
Localizations of the neuroblastoma
  • 75 of tumours occur in the abdomen
  • adrenal medulla 50 ,
  • paraspinal ganglia 25
  • 20 occur in the thorax,
  • 5 occur in the neck and the pelvis

39
The Evans classification for neuroblastoma
  • Stage I tumor confined to an organ of origin.
  • Stage II tumor extending beyond an organ of
    origin, but not crossing the midline. Ipsilateral
    lymph nodes may be involved.
  • Stage III tumor extending beyond midline.
    Bilateral lymph nodes may be involved.
  • Stage IV remote disease involving skeleton, bone
    marrow, soft tissue or distant lymph nodes.
  • Stage IVS same as stage I or II with presence of
    disease in liver, skin or bone marrow.

40
Diagnosis
  • Ultrasonography distinguishes neuroblastoma
    (solid, extrarenal) from cystic lesions and renal
    tumours. The radiographic detection of
    calcification in the tumour is suggestive of
    neuroblastoma. In children with an abdominal
    neuroblastoma, intravenous urography shows
    displacement rather than distortion of the
    pelvicaliceal system. A skeletal survey and chest
    radiograph are mandatory to detect possible
    metastases. CT gives good anatomical data about
    the tumour. Recent studies suggest that magnetic
    resonance imaging (MRI) is useful both to
    delineate the primary tumor and to evaluate bone
    marrow metastasis, vessel involvement, and
    extension into spinal cord.

41
Mediastinal neuroblastoma
                                                
                         ltgt
42
Treatment.
  • The treatment modalities traditionally employed
    in the management of neuroblastoma are surgery,
    chemotherapy, and radiation therapy. The role of
    each method is determined by the natural history
    of individual cases considering stage, age, and
    histological features.

43
Surgery
  • plays the pivotal role in the management of
    neuroblastoma. Depending of the timing, operative
    procedures can have diagnostic as well as
    therapeutic functions. The goals of primary
    surgical procedures, performed before any other
    therapy, are to establish the diagnosis, to
    provide tissue for biological studies, to stage
    the tumor surgically, and to attempt to excise
    the tumor, if feasible. In delayed primary or
    second look surgery, the surgeon determines
    response to therapy and removes residual disease
    when possible.

44
Chemotherapy
  • is the predominant modality of management in
    management in neuroblastoma. Cyclophosphamide,
    vincristine, cisplatin, and doxorubicinare are
    the cornerstone of multiagent management. Drug
    combinations have been developed that take
    advantage of drug synergism, mechanism of
    cytotoxicity, and differences in side effects.

45
Radiation therapy
  • has been used in the multimodality management of
    residual neuroblastoma, bulky unresectable
    tumors, and disseminated disease. More recently,
    the role of radiation therapy in neuroblastoma
    continues to be refined with the improviment in
    multiagentchemotherapyand the increasing trend
    toward developing risk-related treatment groups
    based on age, stage, and biologic features.

46
Classification of Vascular Lesions
  • Vascular malformations (flat lesions)
  • Salmon patch (also known as nevus simplex or
    nevus telangiectaticus)
  • Port-wine stain (also known as nevus flammeus)
  • Hemangiomas (raised lesions)
  • Superficial hemangioma (Cherry, strawberry
    hemangioma)
  • Deep hemangioma (also known as cavernous
    hemangioma)

47
Strawberry haemangiomas
48
Cherry haemangiomas
49
Cavernous haemangiomas
50
After treatment
Before treatment
51
Port wine stains
52
(No Transcript)
53
(No Transcript)
54
Treatment Indications for Hemangiomas
  • Threat to life or function
  • Kasabach-Merritt syndrome (coagulopathy)
  • Anatomic site
  • Vision impairment
  • Respiratory impairment
  • High-output cardiac failure (mortality up to 50
    )
  • Internal lesions
  • Location in scar-prone area
  • Nose, Lip, Ear, Glabellar area
  • Any large facial hemangiomas
  • Pedunculated lesions
  • Tendency to bleed or to become infected
  • Rapid rate of growth (tripling in size within
    weeks)

55
Cavernous lymphangioma
                                                
            ltgt
56
melanoma
naevus
                                                
            ltgt
                                  ltgt
57
melanoma
                                  ltgt
                                  ltgt
Write a Comment
User Comments (0)
About PowerShow.com